ArticleOncology reports2019

Knockdown of ribonucleotide reductase regulatory subunit M2 increases the drug sensitivity of chronic myeloid leukemia to imatinib‑based therapy.

Chunshui Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.